Myocarditis News and Research RSS Feed - Myocarditis News and Research

In medicine (cardiology), myocarditis is inflammation of heart muscle (myocardium). It resembles a heart attack but coronary arteries are not blocked.
Study: Pradaxa drug may increase risk and severity of viral infections

Study: Pradaxa drug may increase risk and severity of viral infections

A study led by researchers at the University of North Carolina indicates that a newly approved blood thinner that blocks a key component of the human blood clotting system may increase the risk and severity of certain viral infections, including flu and myocarditis, a viral infection of the heart and a significant cause of sudden death in children and young adults. [More]

Cardiohelp assists heart by pumping blood to oxygenator in seriously ill patients

A viral infection was causing life-threatening heart failure in Loyola University Medical Center patient Michelle Rivera. [More]
NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD). [More]
Canadian Cardiovascular Society issues new pediatric heart failure guidelines

Canadian Cardiovascular Society issues new pediatric heart failure guidelines

The Canadian Cardiovascular Society is the first in Canada to issue guidelines aimed at helping primary care and emergency physicians, as well as specialists, recognize and manage heart failure in children. The guidelines were released today at the Canadian Cardiovascular Congress. [More]
Alpha-myosin triggers development of autoimmunity after heart attack

Alpha-myosin triggers development of autoimmunity after heart attack

After people with type 1 diabetes have a heart attack, their long-term chance of suffering even more heart damage skyrockets. But the reason has long puzzled scientists. Now researchers at Joslin Diabetes Center have identified the misstep that sparks this runaway chronic damage and a promising way to block it. [More]
FDA approves XenoPort, GSK’s Horizant ER tablets for management of PHN

FDA approves XenoPort, GSK’s Horizant ER tablets for management of PHN

GlaxoSmithKline plc (GSK) and XenoPort, Inc. announced today that the United States (US) Food and Drug Administration (FDA) has approved Horizant (gabapentin enacarbil) Extended-Release Tablets for the management of postherpetic neuralgia (PHN) in adults. [More]
Top-line results from Shire's SPD476 phase 3 trial on diverticulitis

Top-line results from Shire's SPD476 phase 3 trial on diverticulitis

Shire plc, the global specialty biopharmaceutical company, today announced top-line results of the PREVENT2 trial, a phase 3 investigational study of once-daily SPD476, MMX mesalamine in patients with a history of diverticulitis. [More]
Role of cardiovascular magnetic resonance in clinical cardiology

Role of cardiovascular magnetic resonance in clinical cardiology

Cardiovascular Magnetic Resonance (CMR) has undergone substantial development and offers important advantages compared with other well-established imaging modalities. [More]
Insight into role of cytokines in autoimmune diseases

Insight into role of cytokines in autoimmune diseases

Cytokines, a varied group of signaling chemicals in the body, have been described as the software that runs the immune system, but when that software malfunctions, dysregulation of the immune system can result in debilitating autoimmune diseases such as lupus, arthritis, and diabetes. Leading experts in the field of cytokine research present their most up-to-date findings and unique perspectives on the role of cytokines in autoimmune diseases in a special issue of Journal of Interferon & Cytokine Research, a peer-reviewed publication of Mary Ann Liebert, Inc. [More]
FDA approves Shire's Lialda for maintenance of remission of ulcerative colitis

FDA approves Shire's Lialda for maintenance of remission of ulcerative colitis

Shire plc, the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Lialda® (mesalamine) Delayed Release Tablets for the maintenance of remission in patients with ulcerative colitis. [More]
ECG results for young athletes prone to misinterpretation

ECG results for young athletes prone to misinterpretation

Pediatric cardiologists are prone to misinterpreting electrocardiograms when using the results to determine whether young athletes have heart defects that could make exercising perilous, according to a new study from the Stanford University School of Medicine and Lucile Packard Children's Hospital. This is the first research to examine the acumen of pediatric cardiologists from several health-care institutions in using ECGs to detect rare heart conditions associated with sudden cardiac death. [More]
Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb Company today announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY (ipilimumab) prolonged the lives of patients with metastatic melanoma. [More]
Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Bristol-Myers Squibb Company announced today it has entered in to a clinical collaboration agreement with Roche to evaluate the utility of Bristol-Myers Squibb's CTLA-4 inhibitor, YERVOY (ipilimumab), in combination with Roche's investigational oral BRAF inhibitor, vemurafenib, in treating patients with a specific type of metastatic melanoma. [More]
WSU researcher develops potential vaccine for Chlamydia

WSU researcher develops potential vaccine for Chlamydia

A Wayne State University School of Medicine researcher has developed a potential first ever vaccine for Chlamydia, the world's most prevalent sexually transmitted disease and the leading cause of new cases of blindness. [More]

Attacks by specific type of immune cells cause inflammations of heart muscle

Scientists of the German Cancer Research Center, jointly with colleagues in the United States, have found out that inflammations of the heart muscle are caused by attacks of a specific type of immune cells. These immune cells attack the body's own tissue because during their maturation they did not have the chance to develop tolerance against a protein that is only found in the heart muscle. [More]

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration approved YERVOY 3 mg/kg for the treatment of patients with unresectable or metastatic melanoma. [More]

Protein α-myosin could be a promising therapeutic target for myocarditis

Myocardits is an inflammation of the heart muscles that is a major cause of heart failure in young patients. In some cases, the disease is caused by viral infection, but in other patients it is linked to an autoimmune attack on the heart muscle. There are few effective treatment options for myocarditis, in part because the molecular mechanisms that underlie the defect are poorly defined. [More]

Scientists reveal protein target that can trigger myocarditis

People with type 1 diabetes, whose insulin-producing cells have been destroyed by the body's own immune system, are particularly vulnerable to a form of inflammatory heart disease caused by a different autoimmune reaction. [More]
Bluhm Cardiovascular Institute implants VAD device to help individuals with advanced heart failure

Bluhm Cardiovascular Institute implants VAD device to help individuals with advanced heart failure

The Bluhm Cardiovascular Institute of Northwestern Memorial Hospital recently implanted a patient with two of the smallest experimental ventricular assist devices (VADs) currently available for study in humans. VADs are designed to assist either the right (RVAD) or left (LVAD) ventricle, or both (BiVAD) at once. [More]

Young father receives life-saving intervention prior heart transplant surgery

James "Jimmy" Armstrong hadn't missed a "Mac" in 28 years. At 44, he's one of the youngest "goats" in the Chicago Yacht Club. Sailors receive the designation of "goat" once they've completed 20 or more "Macs", the 333-mile boat race from Chicago to Mackinac, Mich. Armstrong has sailed the race every year since he was 16. But, he wasn't among the sailors this past July. Instead, he was in intensive care awaiting heart transplant following a harrowing experience spurred by severe case of myocarditis-a little-known condition causing inflammation of the heart muscle. [More]